Surgical resection remains the most widely used curative approach for hepatocellular carcinoma (HCC), yet the postresection recurrence rate can be as high as 50%-70%. Numerous studies have explored adjuvant therapies for HCC, from the STORM trial in 2015 to the recent IMbrave050 study. However, only a few of these studies have demonstrated positive outcomes.
